These studies, using functional, electrophysiologically active neurons, have predominantly used iPSCs from patients diagnosed with AD with either fAD mutations in APP or PSEN1, or from patients with Down’s syndrome where the duplication of the APP gene results in increased Aβ driving early-onset AD. The gene discussed is APP; the disease is Down syndrome.